Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

2.400 +0.100 (+4.35%)

Streaming Delayed Price Updated: 12:39 PM EDT, Aug 25, 2026 Add to My Watchlist

Price and Volume

Volume	401,030
Open	2.330
Bid (Size)	2.390 (700)
Ask (Size)	2.410 (600)
Prev. Close	2.300
Today's Range	2.330 - 2.480
52wk Range	1.230 - 3.820
Shares Outstanding	55,041,247
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

June 17, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Performance

YTD	-4.8%	-4.8%
1 Month	+14.3%	+14.3%
3 Month	N/A	N/A
6 Month	-7.7%	-7.7%
1 Year	+28.3%	+28.3%

More News

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗

May 22, 2026

Via MarketBeat

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

April 23, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

April 07, 2026

Via ACCESS Newswire

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

March 31, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces $20.2 Million Private Placement Financing

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

March 03, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

January 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Which stocks have an unusual volume on Friday? ↗

November 21, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 19, 2025

Via Benzinga

Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

November 14, 2025

Via ACCESS Newswire

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3

October 30, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 02, 2025

Via Benzinga

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

September 29, 2025

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

September 04, 2025

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - Ordinary Shares publicly traded?

Yes, Connect Biopharma Holdings Limited - Ordinary Shares is publicly traded.

What exchange does Connect Biopharma Holdings Limited - Ordinary Shares trade on?

Connect Biopharma Holdings Limited - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares?

The ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares is CNTB on the Nasdaq Stock Market

What is the current price of Connect Biopharma Holdings Limited - Ordinary Shares?

The current price of Connect Biopharma Holdings Limited - Ordinary Shares is 2.400

When was Connect Biopharma Holdings Limited - Ordinary Shares last traded?

The last trade of Connect Biopharma Holdings Limited - Ordinary Shares was at 08/25/26 12:39 PM ET

What is the market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares?

The market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares is 132.10M

How many shares of Connect Biopharma Holdings Limited - Ordinary Shares are outstanding?

Connect Biopharma Holdings Limited - Ordinary Shares has 132M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.